190
010
Pooled safety results
•
Pooled safety analysis of studies IA05 and 010
•
926 children aged 6 to <12 years
•
Omalizumab was well tolerated
•
No malignancies or deaths were reported in omalizumab‐treated patients
AE = adverse event.
Milgrom H
, et al. Curr Med Res Opin
2011;27:163–9.
Overall incidence
of AEs similar
for omalizumab and placebo
Serious AEs
less common with
omalizumab vs placebo
Omalizumab
n=624
Placebo
n=302
IA05
3.4%
6.6%
91.7%
89.7%
Pooled
Asthma starts early in life
Yunginger JW, et al. Am J Respir Crit Care Med 1992;146:888−94.
0
1000
2000
3000
4000
<1
1−4 5−9 10−14 15−29 30−49 ≥50
Incidence (rates/100,000)
Age group (years)
Incidence of asthma in relation to age and sex
Females
Males
Simposium
